Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer

British Journal of Cancer

Volumn 83, Issue 4, 2000, Pages 443-446

  Simms, M S ^a   Scholfield, D P ^a   Jacobs, E ^b   Michaeli, D ^c   Broome, P ^a   Humphreys, J E ^c   Bishop, M C ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b Aphton Corporatio   (United States)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Anti GnRH antibodies; Hormonal therapy; Prostate cancer

Indexed keywords

AUTOANTIBODY; CANCER VACCINE; GONADORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DRUG TOLERANCE; FLU LIKE SYNDROME; HUMAN; INJECTION SITE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL;

EID: 0033930953     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1315     Document Type: Article

References (15)

1. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Ruckley AR and Sullivan LD (1993) Effects of intermittent androgen suppression on androgen-dependent tumours: apoptosis and serum prostate-specific antigen. Cancer 71: 2782-2790
2. Bradwell AR and Harvey TC (1999) Control of hypercalcaemia of parathroid carcinoma by immunisation. Lancet 353: 370-373
3. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M and Lawson D (1990) Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50: 2275-2282
4. Ferro VA and Stimson WH (1996) Effects of adjuvant, dose and carrier presensitisation on the immunisation efficacy of a GnRH analogue. Drug Des and Discov 14: 179-195
5. Gual G, Garza-Flores J, Menjivar M, Guitierrez-Najar A, Pal R and Talwar G (1997) Ability of an anti-luteinizing hormone-releasing vaccine to inhibit gonadotropins in postmenopausal women. Fert and Steril 67: 404-407
6. Guinan P, Toronchi E, Shaw M, Crispin R and Sharifi R (1982) Bacillus Calmette-Guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology 20: 401-403
7. Halmos G, Arencibia JM, Schally AV, Davis R and Bostwick DG (2000) High incidence of luteinising hormone releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 163: 623-629
8. Huggins C, Hodges C (1941) Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297
9. Jacobs E, Watson SA, Michaeli D, Ellis IO and Robertson JF (1999) Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. Br J Cancer 80(3-4): 352-359
10. Jayashankar R, Chaudhuri MK, Singh O, Alam A and Talwar GP (1989) Semisynthetic vaccine causing atrophy of the prostate. Prostate 14: 3-11
11. Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M and Schally AV (1997) Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 33: 1141-1148.
12. Kirk D for Medical Research Council Prostate Cancer Working Party Investigators (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79: 235-246
13. Stevenson GT (1999) Immunotherapy of non metastatic complication of malignant disease Lancet 353: 340
14. Talwar GP (1997) Vaccines for control of fertility and hormone-dependent cancers. Imm and Cell Bio 75(2): 184-9
15. Walker KJ, Turkes AO, Turkes A, Zwink R, Beacock C, Buck AC, Peeling WB and Griffiths K (1984) Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex®). J Endocrinol 103: R1-R4